Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPO Year: 2021
Exchange: NASDAQ
Website: centurytx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | $6.00 | Buy | Rodman & Renshaw |
| 8/28/2023 | $28.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 12/27/2022 | $19.00 | Buy | Chardan Capital Markets |
| 10/31/2022 | $15.00 | Buy | Guggenheim |
| 10/10/2022 | $28.00 | Buy | Canaccord Genuity |
| 5/23/2022 | $27.00 | Buy | H.C. Wainwright |
| 5/12/2022 | Mkt Perform | William Blair | |
| 11/19/2021 | $33.00 → $32.00 | Outperform | SVB Leerink |
| 7/13/2021 | $34.00 | Buy | BofA Securities |
| 7/13/2021 | $33.00 | Outperform | SVB Leerink |
Fastest customizable press release news feed in the world
Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functionally comparable to primary T cells, now in IND-enabling studies as a potential treatment for B-cell-mediated diseases; program expected to progress into the clinic in 2026 Dr. Brent Pfeiffenberger, CEO, appointed to Board ChairCash runway extended into fourth quarter 2027 PHILADELPHIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune dis
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows: Abstract Number: 1380Title: C
Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and Allo-Evasion™ 5.0 technology PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripoten
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced two presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA. The presentations will highlight data supporting the company's emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer. Details of the presentations are as follows:
PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell therapy programs targeting autoimmune diseases and cancer. The event will feature discussion of CNTY-308, a CD19-targeted CAR-iT investigational cell therapy, CNTY-341, a CD19/CD22 dual-targeted CAR-iT investigational cell therapy, and the company's first solid tumor CAR
Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique profile with transformational potential in autoimmune disease; data anticipated in 2025 Cash runway estimate extended into fourth quarter of 2026 PHILADELPHIA, March 19, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highligh
- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - - Trial to evaluate and enhance clinical experience with CNTY-101 in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis - PHILADELPHIA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, has entered into an agreement for an investigator-init
Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives
PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024: Autoimmune Disease Cell Therapy Panel: 3:00 PM ET Presenter: Chad Cowan, Ph.D., Chief Scientific Officer Fireside Chat: 4:30 PM ET Presenters: Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer A live webcast of the fireside ch
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study – – CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the anticipated protective activity of Century's proprietary Allo-Evasion™ technology – – Ended third quarter 2024 with cash, cash equivalents, and investments of $244.7 million; organizational efficiencies extend expected cash runway into second half of 2026 – PHILADELPH
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
10-Q - Century Therapeutics, Inc. (0001850119) (Filer)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
S-3 - Century Therapeutics, Inc. (0001850119) (Filer)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
144 - Century Therapeutics, Inc. (0001850119) (Subject)
144 - Century Therapeutics, Inc. (0001850119) (Subject)
SCHEDULE 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
10-Q - Century Therapeutics, Inc. (0001850119) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00
JP Morgan downgraded Century Therapeutics from Overweight to Neutral and set a new price target of $5.00 from $28.00 previously
Chardan Capital Markets initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $19.00
Guggenheim initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $15.00
Canaccord Genuity initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $28.00
H.C. Wainwright initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $27.00
William Blair initiated coverage of Century Therapeutics with a rating of Mkt Perform
SVB Leerink reiterated coverage of Century Therapeutics with a rating of Outperform and set a new price target of $32.00 from $33.00 previously
BofA Securities initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $34.00
SVB Leerink initiated coverage of Century Therapeutics with a rating of Outperform and set a new price target of $33.00
Live finance-specific insights
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest
– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due to lack of observed allo-rejection – – Company to host conference call on Monday, December 11 at 7:30 AM PT/10:30 AM ET to review ASH data including additional clinical results from Dose Level 1
PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. In addition to updated preliminary clinical data as of a more re
Reports Fourth Quarter Revenues of $12.0 Billion; Full-Year Revenues of $46.4 Billion Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83; Posts Full-Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51 Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios Advances Pipeline with Achievement of Significant Clinical and Regulatory Milestones; Builds Strong Foundation for Portfolio Renewal Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022 Provides GAAP and More Detailed Non-GAAP Financial Guidance for 2022 Reaffirms Long-term Fi
Live Leadership Updates
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - Six posters to be presented at upcoming AACR Annual Meeting 2024 highlighting Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein en
- Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023. A proven leader with over 20 years of global experience across the healthcare industry, Dr. Pfeiffenberger most recently served as Chief Operating Officer at Neogene Therapeutics, a who
– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting – – Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended first quarter 2023 with cash, cash equivalents, and investments of $334.8 million; Cash runway expected into 2026 – PHILADELPHIA, May 11, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer – – Michael C. Diem, M.D., promoted to Chief Financial Officer – – Hy Levitsky, M.D., rejoins as President of Research and Development – PHILADELPHIA, April 12, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023. Dr. Russotti, who has served as
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently - - Ended third quarter 2022 with cash, cash equivalents, and investments of $395.3 million; Cash runway into 2025 – - Company to host virtual Research and Development Day on Friday, November 11 at 8:00 AM ET - PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We made steady progre
PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Daphne Quimi and Timothy Walbert to the Company's Board of Directors. Ms. Quimi is currently Chief Financial Officer of Amicus Therapeutics and brings experience in public accounting and financial reporting to Century. Mr. Walbert is currently Chairman, President, and Chief Executive Officer of Horizon Therapeutics, and brings expertise in product portfolio building and commercialization. In conjunction with these new appointments, Century also ann
This live feed shows all institutional transactions in real time.
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13D/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)